Drug Database for Digestive Cancers
We often receive the question: ‘which drugs or pharmaceutical treatments (chemotherapy, immunotherapy) are available for patients with digestive cancers? What drugs are available for bowel cancer or colorectal cancer, for gastric cancer, for oesophageal cancer, for liver cancer, pancreatic cancer or for rare digestive cancers?’ This database can give you an indication and answers.
It’s simple to use the database:
- Select which type of digestive cancer you want information about via: ‘Type of Cancer’
- Select whether you are looking for treatments that are still ‘In Development’ or ‘Approved for Market Access’*
*In Development means that these compounds are currently being researched in Phase II (small group of patients) or Phase III (large group of patients). This information is derived from international analyses and from the individual companies involved.
Approved for Market Access means that the European Medicines Agency (EMA) has approved this drug for marketing in the European Union. It does not necessarily mean that this treatment is already available in your country.
Please note the following about the database:
- It is possible that one molecule is already approved for one indication (for instance colorectal cancer) but not yet approved for another type of cancer (for instance gastric cancer).
- In the list you can also see which companies are the ‘marketing authorisation holder’ for the treatment or the developer of the compound, and in which country their headquarters are located.
- It is only indicative and several of the drugs mentioned are indicated for small subpopulations of the cancer mentioned. Please discuss these options with your treating medical team if you want more information on whether it is suitable for you or available.
- ‘Country’ in the table identifies the country of origin of the company developing or selling the medicine
- It is updated once a year, but please let us know if more urgent changes need to be made.
Drug | Company | Country |
---|---|---|
Masitinib (AB-1010) | AB Science | France |
Capecitabine (generic) | Accord Healthcare | United Kingdom |
Lutathera (lutetium Lu 177 dotatate) (NET) | Advanced Accelerator Applications (Novartis) | United States |
Ivosidenib | Agios Pharmaceuticals | United States |
Trastuzumab biosimilar | Allergan | Ireland |
Vectibix (Panitumumab) | Amgen | United States |
Kanjinti (Trastuzumab biosimilar) | Amgen | United States |
Mvasi (Bevacizumab) | Amgen | United States |
AMG 510 (II) | Amgen | United States |
Crenolanib (GIST) (III) | AROG Pharmaceuticals | United States |
Derazantinib (ARQ 087) (III) | ArQule | United States |
Encorafenib (BRAF inhibitor) | Array Biopharmaceuticals | United States |
Ipatasertib | Array Biopharmaceuticals | United States |
Varlitinib (II/III) | Aslan Pharmaceuticals | Singapore |
IMAB362 (zolbetuximab) | Astellas | Japan |
Lynparza POLO | AstraZeneca | United Kingdom/Sweden |
Imfinzi (Durvalumab ) | AstraZeneca | United Kingdom/Sweden |
Lynparza (II) | AstraZeneca | United Kingdom/Sweden |
Imfinzi (Durvalumab) (II) | AstraZeneca | United Kingdom/Sweden |
Tremelimumab (II) | AstraZeneca | United Kingdom/Sweden |
Stivarga (Regorafenib) | Bayer | Germany |
Nexavar(Sorafenib) | Bayer | Germany |
Vitrakvi (Larotrectinib) (NTRK) | Bayer | Germany |
Selitrectinib | Bayer | Germany |
Stivarga (Regorafenib) (II) | Bayer | Germany |
Tislelizumab (BGB-A317) (III) | BeiGene | China |
Opdivo (Nivolumab) | BMS | United States |
Taxol | BMS | United States |
Yervoy (Ipilimumab) | BMS | United States |
Opdivo (Nivolumab) | BMS | United States |
BMS-986183 (II) | BMS | United States |
Linrodostat (BMS-986205) (II) | BMS | United States |
Relatlimab (II) | BMS | United States |
Yervoy (Ipilumab) (III) | BMS | United States |
Bevacizumab Biosimilar (BI 695502) | Boehringer Ingelheim | Germany |
Napabucasin (BBI-608) | Boston Biomedical | United States |
Napabucasin (II) | Boston Biomedical | United States |
Amcasertib (BBI503) | Boston Biomedical | United States |
Namodenoson (CF102) | Can-Fite BioPharma | Israel |
Polyclonal antibody stimulator (III) | Cancer Advances | United States |
Onvansertib (II) | Cardiff Oncology | United States |
ENMD-2076 (II) | CASI Pharmaceuticals | China |
Abraxane | Celgene | United States |
Tislelizumab (BGB-A317) | Celgene | United States |
Herzuma (trastuzumab biosimilar) | Celltrion | Korea |
ThermoDox (doxorubicin liposomal) (III) | Celsion | United States |
Trastuzumab Deruxtecan (DS-8201) (II) | Daiichi Sankyo | Japan |
DCC-2618 (GIST - III) | Deciphera Pharmaceuticals | United States |
eFT508 (II) | eFFECTOR Therapeutics | United States |
Lenvima (Lenvatinib) | Eisai | Japan |
Rivoceranib (III) | Elevar Therapeutics | Korea |
Andecaliximab (II) | Gilead | United States |
bintrafusp alfa | GSK | United Kingdom |
INCB54828 (II) | InCyte | United States |
INCB62079 (II) | InCyte | United States |
Somatuline | Ipsen | France |
Cabozantinib (Cabometyx) | Ipsen | France |
eFT508 (MKNK1/MKNK2 protein inhibitor) | Isofol Medical AB | Sweden |
Modufolin (arfolitixorin) (III) | Isofol Medical AB | Sweden |
Erdafinitib | Janssen | United States |
Imbruvica (ibrutinib) (III) | Janssen | United States |
Famitinib (III) | Jiangsu HengRui Medicine | China |
Ecansya (generic Capecitabine) | Krka | Slovenia |
DKN-01 (anti-DKK1 mAb) (II) | Leap Therapeutics | United States |
Cyramza (Ramucirumab) | Lilly | United States |
Gemzar | Lilly | United States |
Erbitux | Lilly | United States |
Phase III | Lilly | United States |
galunisertib (II) | Lilly | United States |
merestinib (II) | Lilly | United States |
Vinorelbine Tartrate (II) | Lilly | United States |
Capecitabine (generic) | Medac | Germany |
Erbitux (Cetuximab) | Merck | Germany |
Peposertib (M3814, DNA-PK inhibitor) (Phase II) | Merck | Germany |
Bintrafusp Alfa (II and II/III) | Merck | Germany |
Keytruda Phase III | MSD | United States |
Keytruda Phase II (dMMR) | MSD | United States |
Lynparza phase III | MSD | United States |
Ogivri (Trastuzumab biosimilar) | Mylan/Upjohn | United States |
NC-6004 (II) | NanoCarrier | Japan |
Teysuno (Tegafur/Gimeracil/Oteraci) | Nordic Group | France |
Afinitor | Novartis | Switzerland |
Gleevec | Novartis | Switzerland |
Capmatinib (INC280) (II) FGF401 (II) | Novartis | Switzerland |
VPM087 (1L) (II) | Novartis | Switzerland |
Tafinlar (Dabrafenib) | Novartis | Switzerland |
Mekinist (Trametinib) | Novartis | Switzerland |
Ellence (Epirubicin) | Pfizer | United States |
Camptosar (Irinotecan) | Pfizer | United States |
Sutent | Pfizer | United States |
Trazimera (Trastuzumab biosimilar) | Pfizer | United States |
Zirabev (Bevacizumab) | Pfizer | United States |
PM184 (II) | PharmaMar | Spain |
Binimetinib (MEK162) | Pierre Fabre | France |
ensituximab | Precision Biologics | United States |
Infigratinib (BGJ398) | QED Therapeutics | United States |
ABC294640 (Yeliva®) | Redhill BioPharma | United States |
Herceptin® (Trastuzumab) | Roche | Switzerland |
Avastin® (Bevacizumab) | Roche | Switzerland |
Tarceva® (Erlotinib) | Roche | Switzerland |
Xeloda® (Capecitabine) | Roche | Switzerland |
Tecentriq® (Atezolizumab) | Roche | Switzerland |
Tecentriq® (Atezolizumab) (Ib/II) | Roche | Switzerland |
Tecentriq® (Atezolizumab) (III) | Roche | Switzerland |
Tiragolumab (Ib/II) | Roche | Switzerland |
Cotellic® (Cobimetinib) (Ib/II) | Roche | Switzerland |
Cotellic® (Cobimetinib) | Roche | Switzerland |
Avastin® (Bevacizumab) (I) | Roche | Switzerland |
Avastin® (Bevacizumab) (Ib/II) | Roche | Switzerland |
Avastin® (Bevacizumab) (III) | Roche | Switzerland |
Cibisatamab (I) | Roche | Switzerland |
Selicrelumab (Ib/II) | Roche | Switzerland |
RO6874281 (Ib/II) | Roche | Switzerland |
Ontruzant (Trastuzumab biosimilar) | Samsung Bioepis | Korea |
5- Fluorouracil (generic) | Sandoz | Switzerland |
Capecitabine (generic) | Sandoz | Switzerland |
Docetaxel (generic) | Sandoz | Switzerland |
Oxaliplatin (generic) | Sandoz | Switzerland |
Caclium Folinate (generic) | Sandoz | Switzerland |
Irinotecan (generic) | Sandoz | Switzerland |
Gemcitabine (generic) | Sandoz | Switzerland |
Trastuzumab biosimilar | Sandoz | Switzerland |
Taxotere (docetaxel) | Sanofi | France |
Eloxatin (folfox) | Sanofi | France |
Zaltrap (Ziv-Aflibercept) | Sanofi | France |
Lonsurf | Servier | France |
Lonsurf (Tipiracil/Trifluridine) (III) | Servier | France |
Onivyde | Servier | France |
Ph II & Onivyde (PhIII) | Servier | France |
Lonsurf (1L) | Servier | France |
Pexastimogene Devacirepvec (Pexa-Vec) (III) | SillaJen Biotherapeutics | Korea |
Donafenib (III) | Suzhou Zelgen Biopharmaceuticals Co | China |
Entinostat (II) | Syndax Pharmaceuticals | United States |
CMAB009 (III) | Taizhou Mabtech Pharmaceutical | China |
Tirapazamine (TPZ) (II) | Teclison | United States/Taiwan |
Capecitabine (generic) | Teva | Israel |
TRC-105 (II) | TRACON Pharmaceuticals | United States |